NASDAQ:GOSS Gossamer Bio - GOSS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.78 -0.14 (-4.79%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.76▼$2.9850-Day Range$1.74▼$9.2952-Week Range$1.57▼$15.19Volume4.03 million shsAverage Volume3.53 million shsMarket Capitalization$262.65 millionP/E RatioN/ADividend YieldN/APrice Target$10.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Gossamer Bio MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside268.7% Upside$10.25 Price TargetShort InterestBearish38.34% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.75) to ($2.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector393rd out of 1,028 stocksPharmaceutical Preparations Industry188th out of 501 stocks 4.3 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.25, Gossamer Bio has a forecasted upside of 268.7% from its current price of $2.78.Amount of Analyst CoverageGossamer Bio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted38.34% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Gossamer Bio has recently increased by 1.04%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Gossamer Bio is -0.67. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 10 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.30% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions90.18% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to grow in the coming year, from ($2.75) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Gossamer Bio (NASDAQ:GOSS) StockGossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.Read More Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Stock News HeadlinesJanuary 4, 2023 | finance.yahoo.comGossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?January 4, 2023 | finance.yahoo.comGossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 3, 2023 | msn.comLooking Into Gossamer Bio's Recent Short InterestDecember 27, 2022 | msn.com180 Life Sciences, KalVista top healthcare gainers; Edesa, Nutex among losersDecember 26, 2022 | finance.yahoo.comBullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this yearDecember 8, 2022 | seekingalpha.comGossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be UnwiseDecember 7, 2022 | marketwatch.comGossamer Bio: Seralutinib Meets Primary Endpoint in Phase 2 Trial in PAHFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 7, 2022 | seekingalpha.comGossamer Bio downgraded to Equal Weight at Barclays after PAH readoutDecember 7, 2022 | msn.comBarclays Downgrades Gossamer Bio: Here's What You Need To KnowDecember 7, 2022 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About Gossamer BioDecember 7, 2022 | msn.comGossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drugDecember 7, 2022 | proactiveinvestors.comGossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trialDecember 6, 2022 | seekingalpha.comGossamer sheds 63% even as PAH candidate reaches main goal in Phase 2 trialDecember 6, 2022 | seekingalpha.comGossamer Bio selloff is an overreaction - Piper SandlerDecember 6, 2022 | finance.yahoo.comGossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAHNovember 25, 2022 | finance.yahoo.comAnalyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH TrialNovember 17, 2022 | markets.businessinsider.com4 Analysts Have This to Say About Gossamer BioNovember 8, 2022 | msn.comWhat Makes Gossamer Bio (GOSS) a New Buy StockNovember 3, 2022 | finance.yahoo.comGossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business UpdateOctober 24, 2022 | finance.yahoo.comGoldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside PotentialOctober 20, 2022 | forbes.comGossamer BioOctober 20, 2022 | cnbc.comGoldman says buy this under-the-radar biopharma stock expected to rally nearly 80%October 20, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Gossamer BioOctober 18, 2022 | finance.yahoo.comGossamer Bio, Inc. (GOSS)October 17, 2022 | nasdaq.comGossamer Bio, Inc. (NASDAQ:GOSS) is favoured by institutional owners who hold 62% of the companySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Company Calendar Last Earnings11/08/2021Today2/05/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees185Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.25 High Stock Price Forecast$24.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+268.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-234,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-480.17% Return on Assets-76.14% Debt Debt-to-Equity Ratio3.73 Current Ratio5.93 Quick Ratio5.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book1.75Miscellaneous Outstanding Shares94,480,000Free Float86,635,000Market Cap$262.65 million OptionableNot Optionable Beta1.18 Key ExecutivesFaheem HasnainChairman, President & Chief Executive OfficerBryan GiraudoChief Operating & Financial OfficerRichard ArandaChief Medical OfficerLaura CarterChief Scientific OfficerChristian WaageSecretary, General Counsel & Executive VPKey CompetitorsUroGen PharmaNASDAQ:URGNSilverback TherapeuticsNASDAQ:SBTXARS PharmaceuticalsNASDAQ:SPRYLumiraDxNASDAQ:LMDXAlpine Immune SciencesNASDAQ:ALPNView All CompetitorsInsiders & InstitutionsBirchview Capital LPSold 60,000 shares on 2/3/2023Ownership: 0.105%Simplex Trading LLCBought 90,000 shares on 2/2/2023Ownership: 0.000%New York State Common Retirement FundSold 13,733 shares on 1/30/2023Ownership: 0.048%Sequoia Financial Advisors LLCBought 17,500 shares on 1/18/2023Ownership: 0.030%Weiss Asset Management LPBought 2,773,924 shares on 12/6/2022Ownership: 2.936%View All Insider TransactionsView All Institutional Transactions GOSS Stock - Frequently Asked Questions Should I buy or sell Gossamer Bio stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GOSS shares. View GOSS analyst ratings or view top-rated stocks. What is Gossamer Bio's stock price forecast for 2023? 10 brokerages have issued 1 year price targets for Gossamer Bio's stock. Their GOSS share price forecasts range from $2.00 to $24.00. On average, they predict the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 268.7% from the stock's current price. View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts. How have GOSS shares performed in 2023? Gossamer Bio's stock was trading at $2.17 on January 1st, 2023. Since then, GOSS shares have increased by 28.1% and is now trading at $2.78. View the best growth stocks for 2023 here. When is Gossamer Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our GOSS earnings forecast. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) posted its earnings results on Monday, November, 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.02. During the same quarter in the previous year, the company earned ($0.80) EPS. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA). When did Gossamer Bio IPO? (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. What is Gossamer Bio's stock symbol? Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS." Who are Gossamer Bio's major shareholders? Gossamer Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Birchview Capital LP (0.10%), Simplex Trading LLC (0.00%), New York State Common Retirement Fund (0.05%), Sequoia Financial Advisors LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gossamer Bio's stock price today? One share of GOSS stock can currently be purchased for approximately $2.78. How much money does Gossamer Bio make? Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $262.65 million. The company earns $-234,000,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. How many employees does Gossamer Bio have? The company employs 185 workers across the globe. How can I contact Gossamer Bio? Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com. This page (NASDAQ:GOSS) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.